New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

Douglas E. Vaughan*, Joseph Loscalzo

*Corresponding author for this work

Research output: Contribution to journalShort survey

1 Citation (Scopus)

Abstract

The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalTrends in Cardiovascular Medicine
Volume1
Issue number1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Plasminogen Activators
Thrombolytic Therapy
Fibrinolytic Agents
Consensus
Clinical Trials
Safety
Direction compound

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{df63163d5cb042bc9b1180d862c08cbe,
title = "New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates",
abstract = "The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an {"}ideal{"} thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.",
author = "Vaughan, {Douglas E.} and Joseph Loscalzo",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/1050-1738(91)90057-L",
language = "English (US)",
volume = "1",
pages = "36--39",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
number = "1",

}

New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates. / Vaughan, Douglas E.; Loscalzo, Joseph.

In: Trends in Cardiovascular Medicine, Vol. 1, No. 1, 01.01.1991, p. 36-39.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - New directions in thrombolytic therapy. Molecular mutants and biochemical conjugates

AU - Vaughan, Douglas E.

AU - Loscalzo, Joseph

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

AB - The currently available thrombolytic agents are widely perceived to be suboptimal in terms of both efficacy and safety. This perception has in turn stimulated efforts to design and construct novel plasminogen activators endowed with improved biochemical and pharmacologic properties. There is as yet no consensus as to the properties of an "ideal" thrombolytic agent, and the failure of comparative clinical trials to identify a superior agent has contributed to the controversy. Although an improved plasminogen activator has not yet been constructed, it is clear that efforts to do so have advanced our knowledge of the complex structure-function relationships within plasminogen activators.

UR - http://www.scopus.com/inward/record.url?scp=0025767042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025767042&partnerID=8YFLogxK

U2 - 10.1016/1050-1738(91)90057-L

DO - 10.1016/1050-1738(91)90057-L

M3 - Short survey

VL - 1

SP - 36

EP - 39

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 1

ER -